Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt
- 29 November 2017
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 47 (3) , 421-431
Abstract
Summary: Background: Treatment of chronic hepatitis C using combination of sofosbuvir (SOF) and daclatasvir (DCV) was used in several clinical trials and multicentre studies, which were somewhat limited to genotypes 1‐3. The national program in Egypt is using SOF‐DCV combination for large scale treatment.Aim: To assess the efficacy and safety of combined SOF‐DCV in treating patients with HCV‐G4 in a real‐world setting.Methods: Data and outcome of chronic HCV patients who were treated for 12 weeks with generic medications: DCV 60 mg plus SOF 400 mg ± ribavirin (RBV) within the national hepatitis C treatment program in Egypt are presented. Treatment‐naïve patients without cirrhosis were treated without RBV, and those who had cirrhosis or were treatment‐experienced (interferon experienced or SOF experienced) received RBV. Efficacy and safety were assessed, and baseline factors associated with sustained virological response at post‐treatment week 12 (SVR12) were explored.Results: During the first 2 months of the programme, 18 378 patients with HCV‐G4 started treatment with SOF‐DCV with or without RBV. Overall, 95.1% achieved SVR12 (95.4% among patients treated without RBV and 94.7% for patients treated with RBV, P = .32). Treatment was prematurely discontinued in only 1.5% of patients. The most common events leading to discontinuation were patient withdrawal (n = 76) and pregnancy (n = 5). Five deaths occurred within this group.Conclusions: Real‐world experience of generic SOF‐DCV in patients with chronic HCV‐G4 proved to be safe and associated with a high SVR12 rate, in patients with different stages of fibrosis.Keywords
This publication has 35 references indexed in Scilit:
- Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4Journal of Hepatology, 2015
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacyJournal of Hepatology, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6Alimentary Pharmacology & Therapeutics, 2013
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis CNew England Journal of Medicine, 2013
- IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis CJournal of Hepatology, 2012
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 2010
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006